// App-Quantinova.ai

14170 : Reduction in Venous Thromboembolism With Rivaroxaban versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD

Researchers

Presenter

  • Connie N Hess

Principal Investigators

  • Sonia Anand

  • Rupert Bauersachs

  • Manesh R Patel

  • E. Sebastian Debus

  • Mark R Nehler

  • Warren H Capell

  • Lihong Diao

  • Eva Muehlhofer

  • Scott berkowitz

  • Lloyd P Haskell

  • William R Hiatt

  • Marc P Bonaca

Medical Centers

  • Univ of Colorado, Aurora, CO

  • MC MASTER UNIV, Hamilton, Canada

  • Klinikum Darmstadt, Frankfurt

  • UKE Hamburg Eppendorff, Hamburg, Germany

  • UCDENVER VASCULAR SURG, Aurora, CO

  • CPC Clinical Rsch, Aurora

  • BAYER AG, Wuppertal

  • Bayer AG, Whippany, NJ

  • Janssen Pharmaceuticals, Raritan, NJ

Locations

  • United States

  • Canada

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Peripheral artery disease

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • rivaroxaban

  • Clopidogrel bisulfate

  • Aspirin

  • Albyl-E

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved